Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01937676
Recruitment Status : Completed
First Posted : September 9, 2013
Last Update Posted : September 7, 2016
Sponsor:
Information provided by (Responsible Party):
Fredrik Helliksson, Karolinska Institutet

Brief Summary:
The purpose of this study is evaluate if K3, a novel biomarker, sampled at arrival to the emergency department can be used to predict the development of organ failure measured as SOFA score. K3 consists of lactate dehydrogenase, albumin and magnesium combined.

Condition or disease
Multiple Organ Failure

Layout table for study information
Study Type : Observational
Actual Enrollment : 1250 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting
Study Start Date : September 2013
Actual Primary Completion Date : April 2014

Group/Cohort
Adults admitted to ER
All adult patients admitted to emergency department during the study period.



Primary Outcome Measures :
  1. Development of multiple organ failure [ Time Frame: 30 days or complete ICU stay ]
    Measured as SOFA score.


Secondary Outcome Measures :
  1. Cardiac function [ Time Frame: 30 days or complete ICU stay ]
    Is it possible to predict cardiac function with the novel biomarker K3, which consists of lactate dehydrogenase, albumin, and magnesium combined?

  2. All cause mortality [ Time Frame: 30 days after admission to emergency department ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All adult patients admitted to emergency department during study period.
Criteria

Inclusion Criteria:

  • Age ≥18 years
  • Admitted to emergency department, Karlstad Central Hospital, Sweden

Exclusion Criteria:

  • Not in need of venous blood sample

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01937676


Locations
Layout table for location information
Sweden
Karlstad Central Hospital
Karlstad, Sweden
Sponsors and Collaborators
Karolinska Institutet
Investigators
Layout table for investigator information
Principal Investigator: Mathias Karlsson, MD, PhD Karolinska
Study Director: Jan Wernerman, MD, Prof Karolinska
Study Director: Lars Wiklund, MD, Prof Uppsala University
Layout table for additonal information
Responsible Party: Fredrik Helliksson, MD, Karolinska Institutet
ClinicalTrials.gov Identifier: NCT01937676    
Other Study ID Numbers: K3-akuten
First Posted: September 9, 2013    Key Record Dates
Last Update Posted: September 7, 2016
Last Verified: September 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Emergencies
Multiple Organ Failure
Disease Attributes
Pathologic Processes
Shock